Asset Details
Do you wish to reserve the book?
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Do you wish to request the book?
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012
Overview
In a placebo-controlled, phase 2 study, olaparib, an oral PARP inhibitor that should be effective in tumor cells with
BRCA1/2
-related base excision repair defects, increased progression-free survival from 4 months to 8 months in patients with platinum-sensitive relapsed ovarian cancer.
Ovarian cancer is the leading cause of death from gynecologic tumors in the Western world.
1
Approximately 80% of patients with newly diagnosed ovarian cancer have a response to platinum-based chemotherapy. However, most patients have relapses, and responses to subsequent therapies are generally short-lived.
2
–
6
Maintenance chemotherapy as part of first-line treatment has been shown to prolong control of ovarian cancer,
7
and disease control has also been prolonged with the combination of bevacizumab and chemotherapy in patients receiving first-line treatment
8
,
9
and in those with platinum-sensitive relapsed ovarian cancer.
10
However, new treatments are needed because most patients eventually have a relapse. . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - therapeutic use
/ Biological and medical sciences
/ DNA
/ Fatigue
/ Female
/ Gynecology. Andrology. Obstetrics
/ Humans
/ Mutation
/ Nausea
/ Neoplasm Recurrence, Local - drug therapy
/ Ovarian Neoplasms - drug therapy
/ Ovarian Neoplasms - mortality
/ Ovarian Neoplasms - pathology
/ Patients
/ Phthalazines - adverse effects
/ Phthalazines - therapeutic use
/ Piperazines - adverse effects
/ Piperazines - therapeutic use
/ Platinum
/ Ribose
/ Survival
/ Toxicity
/ Tumors
/ Vomiting
